Eli Lilly’s business strategy in 2026 is centered on turning scientific innovation into large, durable pharmaceutical franchises while expanding manufacturing capacity and protecting long-term growth through a broad R&D pipeline.
The company operates as a single pharmaceutical segment, with global R&D responsible for discovering and developing medicines, a global supply organization responsible for manufacturing, and commercial organizations responsible for marketing and distribution. Management explicitly states that long-term success depends on the ability to research and develop innovative medicines while balancing near-term opportunities with long-term pipeline sustainability.
The strategy was highly effective in 2025. Revenue increased 45% to $65.2 billion, while net income rose to $20.6 billion from $10.6 billion in 2024.
Five strategic pillars define Eli Lilly’s business strategy in 2026.
Eli Lilly Business Model 2026: How Does Eli Lilly Make Money?
1. Build Cardiometabolic Health Into Lilly’s Primary Growth Platform
The most important pillar of Lilly’s strategy is expanding its leadership in diabetes, obesity, and related cardiometabolic conditions.
Mounjaro and Zepbound have fundamentally changed Lilly’s revenue mix.
In 2025:
- Mounjaro generated $22.97 billion
- Zepbound generated $13.54 billion
Together, the two products generated approximately $36.5 billion, representing 56% of Lilly’s total revenue.
Growth was extraordinary.
Mounjaro revenue increased 99% globally, while Zepbound revenue increased 175%.
Lilly is also expanding internationally. Mounjaro revenue outside the U.S. increased from $2.6 billion in 2024 to $9.3 billion in 2025, largely because of volume growth.
The strategy goes beyond current products.
Orforglipron has been submitted for regulatory review in the U.S., EU, and Japan for obesity or overweight, as well as in the EU for type 2 diabetes. The FDA also granted it a Commissioner’s National Priority Voucher that could accelerate U.S. review.
This suggests Lilly is building a broader cardiometabolic platform rather than relying on one formulation or molecule.
The strategic logic is:
Mounjaro → Zepbound → expanded indications → international penetration → improved payer access → next-generation products such as orforglipron.
2. Invest Aggressively in Internal R&D and External Innovation
Lilly’s second strategic pillar is maintaining a continuous pipeline of future medicines.
The company spent $13.34 billion on R&D in 2025, up 21% from $10.99 billion in 2024.
The investment is balanced across development stages:
| R&D Category | FY2025 |
|---|---|
| Early-stage R&D | $4.88B |
| Late-stage R&D | $8.46B |
| Total | $13.34B |
Management allocates R&D based on factors including technical probability of success, unmet medical need, commercial viability, and portfolio balance.
But Lilly does not depend only on internal research.
The company also uses:
- acquisitions,
- collaborations,
- licensing,
- strategic investments,
- external technology partnerships.
Lilly describes business development as a way to enhance or refine the pipeline and strengthen the business.
In 2025, acquired in-process R&D charges were approximately $2.91 billion, including transactions involving Scorpion Therapeutics and SiteOne Therapeutics.
Lilly also acquired Verve Therapeutics, which is developing genetic medicines for cardiovascular disease.
The strategy is therefore:
build internally where Lilly has strong capabilities, acquire externally where compelling science exists elsewhere.
This reduces dependence on any single source of innovation.
Eli Lilly PESTEL Analysis 2026
3. Scale Manufacturing to Convert Demand Into Revenue
The third pillar is manufacturing expansion.
For Lilly, demand is no longer the only bottleneck.
The enormous growth of Mounjaro and Zepbound means that production capacity itself has become a strategic growth constraint.
Lilly spent approximately $7.8 billion in capital expenditures in 2025, compared with $5.1 billion in 2024. Management says capital spending will remain meaningfully higher in the near term as it expands global manufacturing capacity.
The company is also using contract manufacturing and long-term supply agreements.
Certain agreements related to medicines in development could require Lilly to pay up to approximately $10 billion if specified purchasing commitments are not met over contract periods generally lasting up to eight years.
This highlights how central supply has become.
The traditional pharmaceutical model emphasizes R&D and patents.
Lilly’s current model adds another equally important capability:
being able to manufacture enough product to meet rapidly increasing demand.
The strategy therefore combines:
drug innovation + capacity expansion + supply-chain resilience.
This is especially important because Mounjaro and Zepbound already represent more than half of company revenue.
4. Expand Patient Access Through Payers and Direct Channels
The fourth strategic pillar is improving patient access.
A medicine can only generate revenue if patients can obtain and afford it.
Lilly operates in a healthcare system where insurers, pharmacy benefit managers, employers, governments, wholesalers, and pharmacies strongly influence access.
Unfavorable formulary placement can reduce product usage through prior authorization, exclusions, higher copays, and higher coinsurance. Lilly states that payer and PBM pressure has negatively affected and could continue to affect financial results.
To address this, Lilly is developing alternative access channels.
The most important is LillyDirect.
LillyDirect allows selected medicines to be delivered through third-party pharmacies while connecting patients with independent healthcare providers and adherence support. Lilly states that self-pay sales through LillyDirect represented a growing portion of the business in 2025.
The company is also expanding government access.
Under preliminary agreements with the U.S. government, Medicare beneficiaries are expected to gain access to discounted Lilly obesity medicines by July 1, 2026, while states can potentially expand Medicaid access.
The strategic goal is therefore not simply maximizing list price.
It is increasing:
patient reach × volume × sustainable net pricing.
This matters because Lilly’s 2025 revenue growth was driven primarily by volume, not pricing. Consolidated volume contributed approximately 50 percentage points of growth, while price reduced growth by around 6 percentage points.
5. Diversify Beyond Tirzepatide to Protect Long-Term Growth
The fifth pillar is portfolio diversification.
The success of Mounjaro and Zepbound is a major strength, but also creates concentration risk.
Six products—Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, and Jardiance—accounted for 82% of 2025 revenue, while Mounjaro and Zepbound alone generated 56%.
Lilly therefore needs to use current cash generation to build future growth engines.
Oncology
Lilly’s oncology portfolio includes Verzenio, Jaypirca, Retevmo, Cyramza, Erbitux, and Inluriyo.
Oncology generated approximately $9.4 billion globally in 2025, including $5.72 billion from Verzenio.
Immunology
Immunology generated approximately $5.25 billion, supported by Taltz, Ebglyss, Omvoh, and Olumiant.
Neuroscience
Neuroscience includes products such as Emgality and Kisunla, giving Lilly exposure to migraine and Alzheimer’s disease.
New Modalities
The acquisition of Verve adds genetic medicine capabilities in cardiovascular disease, while other business-development transactions broaden the future pipeline.
The objective is clear:
use today’s cardiometabolic cash flows to finance tomorrow’s therapeutic platforms.
Intellectual Property Is Central to the Strategy
Lilly’s strategy depends heavily on protecting innovation.
Patent and regulatory exclusivity provide a period during which successful medicines can generate attractive returns on R&D.
For Mounjaro/Zepbound, Lilly lists compound patent protection through approximately:
- 2036 in the U.S.
- 2037 in major European countries
- 2040 in Japan
The company emphasizes that loss of patent protection can result in rapid revenue decline because generic competitors generally spend far less on R&D and can price substantially below branded medicines.
This creates another strategic imperative:
launch new medicines before older products lose exclusivity.
Lilly must therefore manage several product generations simultaneously.
Improve Product Mix and Operating Leverage
The 2025 results demonstrate the financial leverage of Lilly’s strategy.
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenue | $45.04B | $65.18B |
| Gross Margin | 81.3% | 83.0% |
| R&D | $10.99B | $13.34B |
| Marketing, Selling & Administrative | $8.59B | $11.09B |
| Net Income | $10.59B | $20.64B |
Gross margin increased because of favorable product mix and improved production costs, despite lower realized prices.
This shows the importance of mix.
As higher-value products such as Mounjaro and Zepbound become a larger portion of revenue, Lilly can generate substantial incremental profit even while continuing to increase R&D and marketing spending.
Net income almost doubled while revenue increased 45%.
That operating leverage gives Lilly additional resources to reinvest in pipeline development and manufacturing.
Use Partnerships to Extend Capabilities and Share Risk
Lilly also strategically uses collaboration agreements.
Its collaboration with Boehringer Ingelheim contributes to products including Jardiance.
The Ebglyss franchise involves licensing relationships with Roche, Genentech, and Almirall.
Orforglipron was licensed from Chugai Pharmaceutical, which will receive future royalties if the product is successfully commercialized.
These arrangements allow Lilly to access externally developed technologies without necessarily owning all underlying research from inception.
The company can therefore combine:
internal science + external science + global commercialization capability.
This can improve pipeline breadth while sharing development and commercial economics with partners.
Manage Pricing Pressure Rather Than Depend on Price Increases
One of the most important strategic realities for Lilly is that pharmaceutical pricing is becoming increasingly constrained.
In 2025, U.S. volume increased strongly but realized prices declined.
At the consolidated level:
- Volume: +50%
- Price: -6%
- Foreign exchange: +1%
- Revenue growth: +45%
Government pricing programs are becoming increasingly relevant.
Jardiance is subject to Medicare government-set pricing beginning in 2026, while Trulicity and Verzenio were selected for government-set pricing beginning in 2028. Lilly expects additional major products could be selected in future years.
This means Lilly cannot rely primarily on price increases for long-term growth.
Its strategy must increasingly emphasize:
volume growth + new products + new indications + geographic expansion + manufacturing capacity + access.
Financial Strength Supports the Strategy
Lilly’s growth is generating significant internal funding.
Operating cash flow reached approximately $16.8 billion in 2025, compared with $8.8 billion in 2024.
Cash and cash equivalents increased to $7.3 billion.
This financial strength supports:
- R&D,
- manufacturing expansion,
- acquisitions,
- licensing,
- dividends,
- share repurchases,
- debt repayment.
The company also spent $1.5 billion repurchasing shares in the fourth quarter of 2025 under its $15 billion authorization.
The strategic priority, however, is clearly growth investment.
Lilly spent billions simultaneously on R&D, acquired innovation, and manufacturing infrastructure.
The Core of Eli Lilly’s Business Strategy
Lilly’s strategy can be summarized as a reinforcing cycle:
Discover or acquire differentiated medicines → prove clinical value → obtain regulatory approval → secure patent protection → expand manufacturing capacity → improve patient access → scale globally → reinvest cash into the next generation of medicines.
The current cycle is being powered primarily by cardiometabolic health.
Mounjaro and Zepbound provide massive revenue growth.
That cash helps fund:
- orforglipron,
- oncology,
- immunology,
- neuroscience,
- genetic medicine,
- manufacturing,
- acquisitions.
If successful, those investments should reduce dependence on the current incretin franchise over time.
Conclusion
Eli Lilly’s business strategy in 2026 is built around five major priorities:
- Scale the cardiometabolic franchise led by Mounjaro and Zepbound.
- Invest aggressively in internal R&D and external innovation.
- Expand manufacturing capacity to convert demand into revenue.
- Improve patient access through payers, government programs and LillyDirect.
- Diversify the portfolio across oncology, immunology, neuroscience and emerging therapeutic technologies.
The financial results show why Lilly can pursue these priorities aggressively.
Revenue reached $65.2 billion in 2025, up 45%.
Net income reached $20.6 billion.
Gross margin was 83%.
Operating cash flow reached $16.8 billion.
And Mounjaro plus Zepbound alone generated roughly $36.5 billion.
The strategic opportunity is to use the extraordinary economics of the current cardiometabolic franchise to build multiple future franchises before competitive, pricing, or patent pressures eventually reduce the economics of today’s leaders.
In short, Lilly’s strategy is:
win in obesity and diabetes today → reinvest aggressively in science and capacity → create the next generation of blockbuster medicines before the current generation matures.
Source: Eli Lilly Annual Report
